Skip to main content
. 2018 Nov 11;9(23):4556–4567. doi: 10.7150/jca.27368

Figure 2.

Figure 2

Forest plots for ipilimumab plus chemotherapy vs. chemotherapy alone trials of 6months/1year-overall survival(OS) (A/D), 6months/ 1year-progression-free survival(PFS) (B/E), 6months/ 1year-immune-related progression-free survival(irPFS) (C/F).